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745Abstracts
QoL-AGHDA is designed for use in patients with growth
hormone deﬁciency (GHD). It comprises a 25-item ques-
tionnaire that elicits yes/no responses that are used to
compute an aggregate summary index. A high QoL-
AGHDA score denotes poor HrQoL. The survey sample
consisted of 1000 individuals randomly selected from the
UK Population Preference Panel. Individuals were sent a
modiﬁed form of the QoL-AGHDA (including EQ-5D).
The population data were compared with corresponding
data on patients in UK KIMS (Pﬁzer International Meta-
bolic Database). RESULTS: Completed survey forms
were received from 882 individuals (57% female, median
age 55, range 18–90). The mean QoL-AGHDA scores in
the general population was 6.78 (sd = 5.85, n = 868). The
corresponding mean for patients was 14.71 (sd = 5.58, 
n = 841). There was a high degree of correlation with EQ-
5D. Comparison with corresponding data for patients
diagnosed and/or treated for GHD indicate signiﬁcant 
differential patterns of response, with much higher 
QoL-AGHDA scores commensurate with lower levels 
of HrQoL in this group. CONCLUSIONS: This study
reports for the ﬁrst time on the use of QoL-AGHDA in
a UK general population setting. It provides important
evidence on the performance of this condition-speciﬁc
measure as well as calibrating normative reference values.
Additionally it conﬁrmed the discriminant validity of the
measure and demonstrated the health burden of patients
with GHD.
INFECTION
INFECTION—Clinical Outcomes Studies
PIN1
PHARMACEUTICAL MANAGEMENT OF NEWLY
HIV+ DIAGNOSED PATIENTS: RESULTS FROM
THE STAR (SCHEMAS THERAPEUTIQUES-
ANTIRETROVIRAUX) COHORT
Lilliu H1, Rafﬁ F2, Massip P3, Rozenbaum W4, Maurel F1,
Foucher F5, Durand I5, Priol G1,Vincensini JP4, Bugnon F2,
Delpierre C3, Le Pen C1
1Clp-santé, Paris, France; 2CHRU Nantes, Hotel Dieu, Nantes
Cedex 1, France; 3CHU Toulouse Hôpital Purpan,Toulouse,
France; 4Hopital Tenon, Paris, France; 5GlaxoSmithKline, Marly-
Le-Roi, France
OBJECTIVES: To analyze how newly HIV+ diagnosed
patients are managed in 3 French HIV Public Hospitals.
METHODS: STAR is an observational study designed to
prospectively collect electronic data on immunological
and virological status, anti-retroviral therapy (ART) and
medical cost of HIV+ patients. Newly diagnosed (de
novo) patients are exhaustively included in the cohort
since February 2002 in order to identify therapeutic
strategies in the setting of clinical practice. RESULTS: At
the end of March 2003, a total of 328 de novo patients
(65% male) were included, of mean age 36.8 ± 10.5 years,
mainly infected through sexual contacts (49% heterosex-
ual and 27% homosexual). At the time of HIV diagno-
sis, mean CD4 counts and viral load were respectively
368 ± 278 /mm3 and 111,947 ± 164,986 copies/ml. Fifty-
ﬁve patients (17%) had already clinical AIDS status 
and the mean time from seropositivity was 248 ± 104
days. In March 03, 59.5% of patients were without ART
(among whom 94.4% were totally ART-naïve), 36%
were treated with a combination of 3 anti-retrovirals and
4% with 4 anti-HIV drugs. The most frequent combina-
tions were 3 NRTIs (38%) and 2 NRTIs + 1 boosted Pro-
tease Inhibitor (29%). The mean time between HIV
diagnosis and initiation of ART was 66 ± 72 days and the
mean duration of follow-up of non-treated patients was
237 ± 107 days. During the observation period, 29.2%
of treated patients had their treatment changed at least
once, mainly because of drug-related intolerance. A total
of 38% remained under the same ARV combination but
changed at least one molecule. CONCLUSION: These
ﬁndings obtained after 14 months showed signiﬁcant
trends in the management of newly HIV+ diagnosed
patients with a large majority of patients without ART, a
high diversity of initial ART regimens and a high fre-
quency of early interruption.
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OBJECTIVES: Assess the association between unsuccess-
ful initial empiric antibiotic therapy and Health care
resource use among patients undergoing surgery for com-
munity-acquired intra-abdominal infections (CIAI) in
Spain. METHODS: Records of patients who underwent
surgery for CIAI from October 1998 to August 2002 in
hospitals in Spain were reviewed. Empiric antibiotic
therapy was classiﬁed as successful if CIAI was resolved
with initial therapy or with decrease from initial therapy;
and as unsuccessful if IAI was resolved with additional
therapy, additional surgery, died in hospital, or re-
hospitalized within 30 days of discharge. Health care
resource use was measured by hospital length of stay in
days (LOS) and days on IV antibiotic therapy and were
compared between patients with successful and unsuc-
cessful therapy using the non-parametric Kruskal-Walis
test. Least square regression analyses with log transfor-
mation of the outcome variables were performed to assess
associations between unsuccessful IEAT and Health care
resource use measures, after adjusting for patients’ demo-
graphic and co-morbid characteristics as well as site/type
of infection. Four hundred twenty-ﬁve patients were
included. RESULTS: Mean (SD) age was 53.2 (20.7);
40.5% female. 315 (74.1%) patients had successful
therapy (resolved with initial or with decrease from initial
